Our Pharma Insights Blog
Comparator drugs stay on the critical path of most clinical trials. If the comparator is…
September 2026 brought 9 new FDA drug approvals, spanning rare neurological diseases, oncology, diabetes, diagnostic…
Most conversations about clinical trial supply start with the same question: Will the investigational product…
The FDA approved 7 new drugs in August 2026. These approvals introduced new treatment approaches…
Comparator sourcing is one of the most consequential decisions in trial design. Get it wrong,…
Salim Shaikh, Founder and CEO of Spring Bio Solution, has authored a new article, “The…
6 new drugs were approved by the FDA in the month of July. These drugs…
A drug can look brilliant in a single-arm study and fail completely once placed head-to-head…
High-value oncology drugs often come with equally complex clinical supply requirements. OGSIVEO® (nirogacestat) is one…
Every few months, someone in a regulatory affairs forum asks a version of the same…
The Ancillary Problem in Speciality Sourcing: A Market-Intelligence Look at Fintepla® (fenfluramine)
In specialty and comparator sourcing, the working assumption is that the molecule is the hard…
The clock on exclusivity doesn’t start when a patent expires; it starts the moment a…